Multidrug resistance (MDR) is a serious phenomenon employed by cancer cells which
hampers the success of cancer pharmacotherapy. One of the common mechanisms of MDR …

Multidrug resistance (MDR) is the dominant cause of the failure of cancer chemotherapy.
The design of antitumor drugs that are able to evade MDR is rapidly evolving, showing that …

To date, over 100 small-molecule oncology drugs have been approved by the FDA.
Because of the inherent heterogeneity of tumors, these small molecules are often …

A panel of clinically used tyrosine kinase inhibitors were compared and nilotinib was found
to most potently sensitize specific anticancer agents by blocking the functions of ABCB1/P …

Background: Dual-targeting in cancer treatment by a single drug is an unconventional
approach in relation to drug combinations. The rationale for the development of …

The past decade has seen tremendous efforts in the research and development of new
chemotherapeutic drugs using target-based approaches. These efforts have led to the …

The extensive use of tyrosine kinase inhibitors (TKI's) in hematology and oncology has
shown that these drugs have a significant potential for drug‐drug interactions. Since these …

Leiomyosarcoma (LMS) is a soft tissue sarcoma of smooth muscle origin that can arise in
multiple anatomical sites and is broadly classified as extra-uterine LMS or uterine LMS …

The adverse side effects of doxorubicin, including cardiotoxicity and cancer treatment-
related fatigue, have been associated with inflammatory cytokines, many of which are …

The p38MAPK signaling pathway was initially described as a stress response mechanism.
In fact, during previous decades, it was considered a pathway with little interest in oncology …